ArticleFrontiers in molecular neuroscience2025
SIRT3 inhibits autophagy-dependent ferroptosis of HUVECs in the progression of pregnancy-induced hypertension by activating the PI3K/Akt/mTOR axis.
Article in Frontiers in molecular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endocan attenuates LPS-induced alveolar type II cells injury through PI3K/Akt/mTOR pathway.Upsala journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pregnancy-induced hypertension (PIH) is a major contributor to increased maternal and neonatal morbidity and mortality worldwide. Accumulating evidence suggests that vascular endothelial cell injury is a key pathological feature in the development of PIH; however, the underlying molecular mechanisms remain incompletely understood. This study aimed to investigate the role of sirtuin 3 (SIRT3) in regulating autophagy and ferroptosis in endothelial cells under hypoxic conditions, and its potential impact on PIH pathogenesis. Methods: Human umbilical vein endothelial cells (HUVECs) were subjected to hypoxia/reoxygenation (H/R) to mimic ischemic-reperfusion injury associated with PIH. Autophagy levels were assessed by measuring the ratio of microtubule-associated protein light chain 3 (LC3)-II/LC3-I and sequestosome 1/p62 expression. Ferroptosis markers, including intracellular iron, reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), and glutathione peroxidase 4 (GPX4), were evaluated. SIRT3 was overexpressed using pcDNA-SIRT3, and autophagy was modulated with rapamycin or SIRT3 overexpression. The involvement of the PI3K/Akt/mTOR pathway was examined by Western blotting. In vivo validation was performed using a rat model of PIH with SIRT3 overexpression, followed by analysis of placental tissue for relevant protein expression and signaling pathway activation. Results: H/R treatment induced autophagy in HUVECs, as evidenced by increased LC3-II/LC3-I ratio and decreased p62 levels. It also triggered ferroptosis, characterized by elevated iron, ROS, and MDA levels, along with reduced GSH and GPX4 expression. Overexpression of SIRT3 suppressed both H/R-induced autophagy and ferroptosis, and these protective effects were reversed by the autophagy inducer rapamycin or the ferroptosis inducer erastin. Mechanistically, SIRT3 activated the PI3K/Akt/mTOR signaling pathway, and inhibition of this pathway attenuated the suppressive effects of SIRT3 on autophagy and ferroptosis. In PIH rats, SIRT3 overexpression increased the levels of SIRT3 and GPX4, enhanced phosphorylation of PI3K, Akt, and mTOR, and reduced the LC3-II/LC3-I ratio in placental tissues compared to control PIH rats. Discussion: These findings demonstrate that SIRT3 protects against hypoxia-induced endothelial cell injury by inhibiting autophagy-dependent ferroptosis through activation of the PI3K/Akt/mTOR signaling pathway. The in vivo results further support a protective role of SIRT3 in alleviating PIH. This study reveals a novel SIRT3-mediated regulatory mechanism in PIH pathophysiology, suggesting that targeting SIRT3 and its downstream signaling may represent a potential therapeutic strategy for the management of PIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.